Inogen, Inc. INGN
Inogen's growth story rests on a fabricated TAM sourced from a plagiarism-riddled WinterGreen report; real market is shrinking, peak sales arrive 2019-2020, target $46 (-67%).
Thesis
Muddy Waters is short Inogen because management has manufactured a false growth narrative around a Total Addressable Market it claims is 3+ million U.S. ambulatory oxygen users growing 7-10%. Using CMS Medicare data, Muddy Waters calculates the real U.S. TAM at roughly 1.3 million users and shows the market actually contracted at a -2.6% CAGR from 2010 to 2017. The 3-million figure traces back to WinterGreen Research, an obscure firm whose 2017 report contains plagiarism from the New York Times, citations of a non-existent Prudential 150-year-old projection, and middle-school-grade prose. Compressing margins, a 177-bps Q3 2018 provision-release gimmick, ballooning ad spend, and a B2B mix shift signal saturation; Muddy Waters models peak sales of ~$400M in 2019/2020 and values INGN at $46 versus $139.74, a 67% decline.
SCQA
Inogen sells portable oxygen concentrators (POCs) at a 50x+ multiple, supported by a story of a $3-4bn U.S. TAM with 3M+ ambulatory oxygen users growing 7-10% annually and only ~11% POC penetration.
CMS Medicare data shows the real U.S. TAM is only ~1.3M users and is shrinking at -2.6% CAGR; the 3M figure comes from WinterGreen Research, a report riddled with plagiarism, typos, and impossible claims like 150-year-old federal judges.
Short INGN: discredit the WinterGreen-sourced TAM narrative, expose the Q3 2018 provision-release accounting gimmicks, and recognize that B2B mix shift and saturating penetration force peak sales in 2019 or 2020.
At peak earnings of ~$47M with no growth, INGN deserves a 21x P/E like saturated medical-device peers, implying a $46 target price and 67% downside from $139.74.
The three reasons
- 1
Real U.S. TAM is 1.3M users, 57% below management's 3M+ claim
- 2
Oxygen therapy market actually shrinking at -2.6% CAGR, not growing 7-10%
- 3
Q3 2018 gross margin boosted 177 bps via accounting gimmicks masking decline
Primary demands
- Sell INGN shares: target $46 (-67% downside)
- Discount management TAM and growth claims based on WinterGreen Research
- Recognize peak sales arriving in 2019 or 2020 and impending de-rating
KPIs cited
Pattern membership
Where this document fits across the library's 12 rhetorical / structural patterns.
Notable slides (6)
Notes
Classic Muddy Waters short report format: cover with Carson Block byline and disclaimer (p1), summary box with target price (p2), Richard Pryor 'lyin' eyes' epigraph opener (p3), then dense prose with embedded CMS data tables, screenshots of management slides as exhibits, and quoted contradictions from earnings calls. The most cinematic rhetorical move is the WinterGreen takedown (pp11-13): plagiarism from the NYT shown side-by-side, the Prudential '150-year-olds' billboard reproduced, and the 'federal judges working past 100' quote. Closing peer-comp valuation table with $46 target and -67% return on final page. Document type chosen as research_note (text-dominant) rather than full_deck. visual_quality=2 because layout is plain Word/PDF body text with utilitarian charts, not deck-style design.